AbbVie (TSX:ABBV) Other Current Liabilities: C$0 Mil (As of Mar. 2026)


TSX:ABBV AbbVie Inc TSX:ABBV
81 GF Score
Price C$35.51
GF Value C$29.99
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Other Current Liabilities?

AbbVie TSX:ABBV -3.79% 81 Other Current Liabilities is C$0 Mil as of Mar. 2026. GuruFocus rates TSX:ABBV with a GF Score™ of 81/100 and a GF Value™ of C$29.99 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's other current liabilities for the quarter that ended in Mar. 2026 was C$0 Mil.

AbbVie's quarterly other current liabilities increased from Sep. 2025 (C$-0 Mil) to Dec. 2025 (C$0 Mil) but then from Dec. 2025 (C$0 Mil) to Mar. 2026 (C$0 Mil).

AbbVie's annual other current liabilities declined from Dec. 2023 (C$-0 Mil) to Dec. 2024 (C$-0 Mil) but then increased from Dec. 2024 (C$-0 Mil) to Dec. 2025 (C$0 Mil).

AbbVie Other Current Liabilities Related Terms

AbbVie Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for AbbVie's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Other Current Liabilities Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 -0.00 0.00

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00
TSX:ABBV
81GF Score
AbbVie Inc TSX:ABBV
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of C$0 Mil mean?
AbbVie (TSX:ABBV) has a Other Current Liabilities of C$0 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AbbVie.
Is AbbVie's Other Current Liabilities too high?
AbbVie's current Other Current Liabilities is C$0 Mil. Overall, AbbVie has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Other Current Liabilities compare to MRK and JNJ?
AbbVie's Other Current Liabilities of C$0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AbbVie. AbbVie's current Other Current Liabilities is C$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (TSX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is C$29.99, compared to a current price of C$35.51 — trading 18.4% above its estimated fair value. The current Other Current Liabilities is C$0 Mil. AbbVie's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For AbbVie (TSX:ABBV), the current Other Current Liabilities is C$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (TSX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of C$35.51 is trading 18.4% above its estimated GF Value™ of C$29.99. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for TSX:ABBV:

  • Other Current Liabilities: C$0 Mil
  • GF Value™: C$29.99 vs. price of C$35.51 (18.4% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the TSX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
81GF Score

Get the complete analysis for TSX:ABBV

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$35.51
Price
C$29.99
GF Value